These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 30609008)

  • 1. Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis.
    Romiti R; Valenzuela F; Chouela EN; Xu W; Pangallo B; Moriarty SR; Gürbüz S; Riedl E
    Br J Dermatol; 2019 Jul; 181(1):202-203. PubMed ID: 30609008
    [No Abstract]   [Full Text] [Related]  

  • 2. Integrated safety analysis: Frequency of urinary tract infections in patients with psoriasis treated with ixekizumab.
    Smith SD; Conrad C; Ramharter M; Gottlieb AB; Patel H; Xu W; Riedl E; Schuster C
    J Am Acad Dermatol; 2020 Jul; 83(1):261-263. PubMed ID: 32092375
    [No Abstract]   [Full Text] [Related]  

  • 3. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
    Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
    J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.
    Syed YY
    Am J Clin Dermatol; 2017 Feb; 18(1):147-158. PubMed ID: 28138946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience.
    Conti A; Peccerillo F; Amerio P; Balato A; Bardazzi F; Bianchi L; Burlando M; Cannavò SP; Chiricozzi A; Dapavo P; De Simone C; Fargnoli MC; Gambardella A; Gisondi P; Malagoli P; Malara G; Mugheddu C; Offidani AM; Piaserico S; Prignano F; Stingeni L; Pellacani G
    Br J Dermatol; 2019 Jun; 180(6):1547-1548. PubMed ID: 30578668
    [No Abstract]   [Full Text] [Related]  

  • 6. Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy.
    Giunta A; Ventura A; Chimenti MS; Bianchi L; Esposito M
    Drug Des Devel Ther; 2017; 11():1643-1651. PubMed ID: 28652702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: A single-center experience.
    Ohata C; Ohyama B; Katayama E; Nakama T
    J Dermatol; 2020 Apr; 47(4):405-408. PubMed ID: 31994229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
    Kimura R; Sugita K; Yamamoto O
    Eur J Dermatol; 2020 Dec; 30(6):732-734. PubMed ID: 33237034
    [No Abstract]   [Full Text] [Related]  

  • 9. Eyelid Dermatitis as a Side Effect of Interleukin-17A Inhibitors in Psoriasis.
    Teraki Y; Takahashi A; Inoue Y; Takamura S
    Acta Derm Venereol; 2018 Apr; 98(4):456-457. PubMed ID: 29327064
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety of secukinumab in psoriasis patients with latent tuberculosis infection.
    Machado Á; Abreu M; Torres T
    Eur J Dermatol; 2020 Dec; 30(6):740-741. PubMed ID: 33237033
    [No Abstract]   [Full Text] [Related]  

  • 11. Pleural Fluid Eosinophilia: A Possible Adverse Event of Interleukin-17 Inhibition.
    Hayashi W; Osada SI; Toyoshima A; Yamada K; Sudo K; Nakayama K; Manabe M
    Acta Derm Venereol; 2019 Nov; 99(12):1174-1175. PubMed ID: 31502653
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice.
    Georgakopoulos JR; Phung M; Ighani A; Yeung J
    J Cutan Med Surg; 2019; 23(2):174-177. PubMed ID: 30449146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies.
    Wu CY; Chiu HY; Tsai TF
    PLoS One; 2019; 14(12):e0225112. PubMed ID: 31881026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ixekizumab for the treatment of psoriasis: an update on new data since first approval.
    Blegvad C; Skov L; Zachariae C
    Expert Rev Clin Immunol; 2019 Feb; 15(2):111-121. PubMed ID: 30589394
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.
    Zachariae C; Gordon K; Kimball AB; Lebwohl M; Blauvelt A; Leonardi C; Braun D; McKean-Matthews M; Burge R; Cameron G
    J Am Acad Dermatol; 2018 Aug; 79(2):294-301.e6. PubMed ID: 29653208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis.
    Mrowietz U; Riedl E; Winkler S; Xu W; Patel H; Agada N; Lebwohl MG
    J Am Acad Dermatol; 2020 Nov; 83(5):1436-1439. PubMed ID: 32526319
    [No Abstract]   [Full Text] [Related]  

  • 19. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed.
    Kimmel G; Chima M; Kim HJ; Bares J; Yao CJ; Singer G; Kim SJ; Bagel J; Lebwohl M
    J Am Acad Dermatol; 2019 Sep; 81(3):857-859. PubMed ID: 31078609
    [No Abstract]   [Full Text] [Related]  

  • 20. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition.
    Napolitano M; Megna M; Fabbrocini G; Nisticò SP; Balato N; Dastoli S; Patruno C
    Br J Dermatol; 2019 Sep; 181(3):604-606. PubMed ID: 30768788
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.